

Vaccination Report – 21 Sep 2021

1. Vaccine Implementation

- WHO's Emergency Use Listing(EUL) Vaccines (Last Updated 19 August 2021)

| | Manufacturer | Name of Vaccine | NRA of Record | Vaccine type |
|---|----------------------------------|------------------------------|--|--------------------------------|
| 1 | Pfizer-BioNTech (US) | BNT162b2 | EMA/USFDA | mRNA |
| 2 | AstraZeneca (UK) | ChAdOx1 (AZS1222) | EMA/ MFDS KOREA/ Japan MHLW/PMDA/ Australia TGA | Non ReplicatingViral vector |
| 3 | Serum Institute of India (India) | Covishield (ChAdOx1_nCoV-19) | DCGI | Non Replicating Viral Vector |
| 4 | Johnson &Johnson (US) | Ad26.CoV2.S | EMA | Non ReplicatingViral vector |
| 5 | Moderna (US) | mRNA-1273 | EMA/USFDA | mRNA |
| 6 | Sinopharm Beijing (China) | BBIBP-CorV | NMPA | Inactivated virus (Vero Cells) |
| 7 | Sinovac (China) | SARS-CoV-2 Vaccine | NMPA | Inactivated virus (Vero Cell) |

- **22** Vaccines Approved by at Least One Country

| Vaccine Type | mRNA | Non Replicating Viral vector | Inactivated virus | Protein Subunit | DNA | Total |
|--------------|------|------------------------------|-------------------|-----------------|-----|-----------|
| In Use | 3 | 6 | 8 | 4 | 1 | 22 |

Source: <https://covid19.trackvaccines.org/vaccines/> (Last Updated 17 Sep 2021)

- Vaccination against COVID-19 has now started in **217** locations

(Source: Our World in Data.Last Updated 20 Sep 2021)

| Location | Doses given | Fully vaccinated (% of population) | At least 1 dose (% of population) |
|-----------|--------------|------------------------------------|-----------------------------------|
| Worldwide | 5.98 billion | 2.51 billion (31.85%) | 3.43 billion (43.55%) |

About this data:

a: This data changes rapidly and might not reflect doses still being reported. It may differ from other sites & sources.

b: Where data for full vaccinations is available, it shows how many people have received at least 1 dose and how many people have been fully vaccinated (which may require more than 1 dose). Where data for full vaccinations isn't available, the data shows the total number of vaccine doses given to people. Since some vaccines require more than 1 dose, the number of fully vaccinated people is likely lower.


c: It only has full vaccination totals in some locations.

Share of people vaccinated against COVID-19, Sep 20, 2021



Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

■ Share of people fully vaccinated against COVID-19 ■ Share of people only partly vaccinated against COVID-19




Source: Official data collated by Our World in Data. This data is only available for countries which report the breakdown of doses administered by first and second doses in absolute numbers.
CC BY

Share of the population fully vaccinated against COVID-19



Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.




Source: Official data collated by Our World in Data – Last updated 21 September 2021, 11:00 (London time)
Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.
OurWorldInData.org/coronavirus • CC BY

COVID-19 vaccination policy



This metric records policies for vaccine delivery for different groups.

- Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for all three plus partial additional availability (select broad groups/ages)
- Universal availability



Source: Oxford COVID-19 Government Response Tracker, Blavatnik School of Government, University of Oxford – Last updated 21 September 2021, 04:50 (London time)
OurWorldInData.org/coronavirus • CC BY

2. Vaccine effectiveness against symptomatic infection for Alpha and Delta variants

| Vaccine Status | Vaccine Effectiveness | |
|--------------------------------------|--|---|
| | Alpha | Delta |
| 1 Dose (BNT162b2 or ChAdOx1 nCoV-19) | 48.7% (95%CI: 45.5-51.7%) ¹ 66%(BNT162b2) ⁴ 64% (ChAdOx1) ⁴ | 30.7% (95%CI: 25.2-35.7%) ¹ 56%(BNT162b2) ⁴ 67%(ChAdOx1) ⁴ |
| 1 Dose (mRNA-1273) | 83% ⁴ | 72% ⁴ |
| 1 Dose(Sinopharm or Sinovac) | Unknown | 13.8%,(95%CI: -60.2-54.8%) ³ |
| 2 Doses (BNT162b2) | 93.7% (95%CI: 91.6-95.3) ¹ 76% (95%CI: 69-81%) ² 89% ⁴ | 88% (95%CI: 85.3-90.1%) ¹ 42% (95% CI: 13-62%) ² 87% ⁴ |
| 2 Doses (ChAdOx1 nCoV-19) | 74.5% (95%CI: 68.4-79.4%) ¹ | 67.0% (95%CI: 61.3-71.8%) ¹ |
| 2 Doses (mRNA-1273) | 86%, (95%CI: 81-90.6%) ² | 76%, (95% CI: 58-87%) ² |
| 2 Doses(Sinopharm or Sinovac) | Unknown | 59.0%, (95%CI: 16.0-81.6%) ³ |

References:

- 1) [Effectiveness of Covid-19 Vaccines against the B.1.617.2 \(Delta\) Variant](#)
- 2) [Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence](#)
- 3) [Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study](#)
- 4) [Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada](#)

3. Latest Relevant Articles

- [mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants](#)

4. Other Information

- [U.S. is going to open air travel to most vaccinated travelers in November.](#)
- [CDC:Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021](#)
- [CDC: Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen \(Johnson & Johnson\) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021](#)
- [Pfizer and BioNTech announced positive results from pivotal trial of COVID-19 vaccine in children 5 to 11 years](#)
- [Johnson & Johnson announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered.](#)